The use of antidiabetic drug is to be expanded in treating non-alcoholic steatohepatitis (NASH) as the Korean Association for the Study of the Liver (KASL) gave a priority recommendation on prescription of pioglitazone.

The prospective prescription strategy is likely to see a significant change as a glucagon-like peptide 1 receptor agonist (GLP-1 RA) semaglutide, becoming a star obesity drug with exceptional weight-loss effect, has emerged as a new key treatment option.

# On Feb. 17, KASL convened an online hearing session to revise the NASH treatment guideline and unveiled the first draft of the revision scheduled to be published on Mar. 5.

The guideline would vastly re